Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bile Acid Reflux Causes Gastric Ulcers, Cancer: Prof. Haruma
January 15, 2007
- FPMAJ to Propose New Drug Pricing Rule: President Morita
January 15, 2007
- NPhA to Focus on Its Incorporation, Increase in Membership
January 15, 2007
- HPB's Budget Earmarks \90 Mil. to Fund Training of CRCs
January 15, 2007
- JT Licenses Antibody Drug Candidate to MedImmune
January 15, 2007
- PMDA Begins Drafting a New Review Policy
January 15, 2007
- Korosho to Conduct New Survey on Price Agreement Rates
January 15, 2007
- REGULATORY NEWS IN BRIEF ―１―
January 15, 2007
- Drug Industry in Japan Has Wind at Its Back
January 8, 2007
- Most Medical Institutions Leery of Generics Despite Increased Use
January 8, 2007
- Shionogi, DSP to Enter ARB Market with Irbesartan
January 8, 2007
- Generic Entry Should Be Permitted in the Absence of Original Products: Ihoken
January 8, 2007
- Sales to Break \80 Bil. in 2006: Schering-Plough
January 8, 2007
- GENERIC NEWS IN BRIEF
January 8, 2007
- Teijin to Invest in New Businesses Including Healthcare
January 8, 2007
- MEDICAL DEVICE NEWS IN BRIEF
January 8, 2007
- BUSINESS NEWS IN BRIEF
January 8, 2007
- Hospitals to Demand that Insurers Pay Unpaid Copayments
January 8, 2007
- JPLA Seminae
January 8, 2007
- J&J Extends Its SOHO Day System to Include Employees with School Children
January 8, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…